NHS England announces new specialised treatments for patients.
NHS England has today announced the results of the first of two prioritisation rounds to decide which new specialised commissioning treatments and services will be made available for patients for the 2018/19 financial year.
An initial three new treatments and services were approved for funding including a treatment for HIV, a new specialised service for adults with primary ciliary dyskinesia, a genetic disorder affecting the respiratory system, and a new specialised service for Stevens-Johnson syndrome, a serious disorder of the skin.
Funding for the new treatments and services will begin from April and will benefit an estimated 3000 patients in the first year and thousands more annually after that.
All the proposed new treatments were independently assessed for their clinical benefit and cost by the Clinical Priorities AdvisoryGroup (CPAG) made up of doctors, health experts and patient representatives.
The prioritisation process for new investment decisions has now moved from an annual cycle to twice a year, in order to speed up the introduction of important new evidence-based treatments and services for patients. Today’s announcement represents the first set of decisions for investment in 2018/19 with a second set of prioritisation decisions to be taken next May.
Further treatments from this list, and other areas, will be considered in May, and if successful could be introduced by June.
Treatments are grouped into five levels of priority, with those that cost less and offer more clinical benefit for patients classified as level one, and treatments with the lowest clinical benefit and highest cost placed in the lowest category (level five).
At this time we are approving treatments in levels one and two and the new service proposal in level three. The remaining two treatments in level three will continue to remain available to NHS patients via the Cancer Drugs Fund. All other treatments listed will be considered again at the second round in May 2018.
- Service Specification for patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS-TEN) (all ages)
- Immediate antiretroviral therapy for treatment of HIV-1 in adults and adolescents
- Service Specification for adults with the genetic condition, primary ciliary dyskinesia (PCD)
- Bendamustine with rituximab for first line treatment of non-Hodgkin’s lymphoma
- Bendamustine with rituximab for first line treatment of mantle cell lymphoma
- Artificial cornea for corneal blindness
- Inhaled therapy for people with cystic fibrosis and lung infections caused by bacteria pseudomonas aeruginosa
- Bendamustine with rituximab for treatment of relapsed mantle cell lymphoma
- No proposals fell into level 5
Latest News from
Pre-election guidance for the 2019 General Election07/11/2019 16:15:00
This pre-election guidance will help organisations make all staff aware of the implications on communications activities of the period prior to the 2019 general election.
New NHS online training to help people get home from hospital quicker05/11/2019 16:51:00
NHS England and Health Education England have today launched ActNow, an e-learning tool developed for health service and care staff to help them reduce hospital delays for patients.
Demand for NHS burns care soars over bonfire night and diwali04/11/2019 14:15:00
Top doctors from the NHS and St John Ambulance have teamed up to urge revellers to stay safe during Guy Fawkes Night and Diwali celebrations, as new figures reveal thousands end up in hospital each year due to firework and bonfire injuries.
Public back NHS plans for new rapid care measures01/11/2019 14:25:00
England’s top doctor has welcomed new polling showing that patients and the public support NHS proposals focussing on fast treatment for those who need it in A&E.
NHS ramps up drive to increase uptake of lifesaving vaccines28/10/2019 09:15:00
More lifesaving vaccines should be provided in convenient locations for parents to drive uptake, a new NHS review shows.
NHS England concludes wide-ranging deal for cystic fibrosis drugs24/10/2019 12:20:00
NHS England has today announced it has secured a definitive agreement with Vertex Pharmaceuticals to make available all three of their UK-licensed cystic fibrosis medicines.
Tens of thousands given life changing diabetes monitors thanks to the NHS Long Term Plan22/10/2019 14:15:00
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan.
World Antibiotic Awareness Week, 18-22 November22/10/2019 09:15:00
World Antibiotic Awareness Week (WAAW) aims to increase awareness of antibiotic resistance as a global problem, and to promote best practices among the general public, health workers and policy-makers to avoid the further emergence and spread of antibiotic resistance.